Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CEO Ying Du sold 46,387 shares of the business's stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $35.47, for a total transaction of $1,645,346.89. Following the transaction, the chief executive officer owned 536,962 shares in the company, valued at $19,046,042.14. The trade was a 7.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Ying Du also recently made the following trade(s):
- On Friday, August 8th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $34.74, for a total transaction of $1,737,000.00.
- On Monday, August 11th, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $34.64, for a total transaction of $1,732,000.00.
- On Wednesday, July 2nd, Ying Du sold 7,072 shares of Zai Lab stock. The stock was sold at an average price of $35.23, for a total transaction of $249,146.56.
- On Monday, June 30th, Ying Du sold 6,918 shares of Zai Lab stock. The stock was sold at an average price of $35.52, for a total transaction of $245,727.36.
- On Thursday, June 26th, Ying Du sold 23,669 shares of Zai Lab stock. The stock was sold at an average price of $36.13, for a total transaction of $855,160.97.
Zai Lab Price Performance
Shares of ZLAB stock traded down $0.70 during trading hours on Thursday, hitting $34.93. The company had a trading volume of 292,739 shares, compared to its average volume of 988,061. The company's fifty day moving average is $36.76 and its 200 day moving average is $33.38. Zai Lab Limited Unsponsored ADR has a fifty-two week low of $16.03 and a fifty-two week high of $44.34. The stock has a market capitalization of $3.88 billion, a PE ratio of -17.12 and a beta of 1.03.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.37). The firm had revenue of $109.98 million during the quarter, compared to analysts' expectations of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Equities analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts have weighed in on ZLAB shares. Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the company an "outperform" rating in a research report on Monday, June 30th. Wall Street Zen lowered shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Finally, Citigroup restated a "buy" rating and issued a $69.00 price objective (up from $66.00) on shares of Zai Lab in a report on Monday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.22.
Check Out Our Latest Analysis on ZLAB
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Principal Financial Group Inc. grew its holdings in shares of Zai Lab by 63.6% in the first quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock valued at $104,257,000 after purchasing an additional 1,121,856 shares in the last quarter. RTW Investments LP acquired a new position in shares of Zai Lab in the fourth quarter valued at approximately $65,714,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Zai Lab by 30.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,354,025 shares of the company's stock valued at $61,653,000 after purchasing an additional 548,378 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Zai Lab by 46,222.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock valued at $77,058,000 after purchasing an additional 2,127,598 shares in the last quarter. Finally, Allianz Asset Management GmbH grew its holdings in shares of Zai Lab by 25.1% in the first quarter. Allianz Asset Management GmbH now owns 1,884,411 shares of the company's stock valued at $68,103,000 after purchasing an additional 378,545 shares in the last quarter. Institutional investors and hedge funds own 41.65% of the company's stock.
Zai Lab Company Profile
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access